Advertisement

Topics

Phase I/II Single Center, Single-Treatment, Open-Label, Adaptive Clinical Trial Design Examining Pk of 2 MR Formulations of MPH in Adolescent/Pediatric With ADHD

2014-10-03 16:35:33 | BioPortfolio

Published on BioPortfolio: 2014-10-03T16:35:33-0400

Clinical Trials [2574 Associated Clinical Trials listed on BioPortfolio]

A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD

This study will examine the efficacy and safety of HLD200 (methylphenidate) in patients age 6-12 years with ADHD. This study has a 6-week dose optimization period followed by a one week do...

A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting

This Phase 3 pivotal efficacy trial will examine the effects of HLD200 (methylphenidate) in patients aged 6-12 years with ADHD in a naturalistic setting. Following a screening/washout peri...

A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting

This Phase 3 pivotal efficacy trial will examine the effects of HLD200 (methylphenidate) in patients aged 6-12 years with ADHD in a laboratory classroom setting. This study has a 6-week op...

Attention Deficit Hyperactivity Disorder (ADHD) Prediction of Treatment Response

This is a 6-month open-label, randomized control trial in adults to find out if certain neuromarkers can predict individual treatment response to stimulant medications for Attention Defici...

Concerta (Methylphenidate) -To-Generic Switch Study

The primary purpose of this study is to identify whether, after adjustment for confounders via stratification on a propensity score and adjustment for calendar year, the combined endpoint ...

PubMed Articles [8993 Associated PubMed Articles listed on BioPortfolio]

Population Pharmacokinetic-Pharmacodynamic Modeling of a Novel Methylphenidate Extended-Release Orally Disintegrating Tablet in Pediatric Patients With Attention-Deficit/Hyperactivity Disorder.

A methylphenidate (MPH) extended-release orally disintegrating tablet (MPH XR-ODT) formulation was recently approved for attention-deficit/hyperactivity disorder treatment in children 6 to 17 years of...

The Impact of Vitamin D Supplementation on Attention-Deficit Hyperactivity Disorder in Children.

The role of nutrients and dietary factors in attention-deficit hyperactivity disorder (ADHD) remains unclear.

Translation and validation of the Brown attention-deficit disorder scale for use in Brazil: identifying cases of attention-deficit/hyperactivity disorder among samples of substance users and non-users. Cross-cultural validation study.

The Brown Attention-Deficit Disorder Scale (BADDS) was developed as a self-report assessment that was designed to screen for presence of symptoms of attention deficit hyperactivity disorder (ADHD). Th...

Predicting attention deficit hyperactivity disorder using pregnancy and birth characteristics.

The aim of this study was to evaluate maternal, prenatal, perinatal, and postpartum parameters as risk factors for the later development of an attention deficit hyperactivity disorder (ADHD) in the ch...

Clinical Utility of the Korean Version of the WHO Adult Attention-Deficit/Hyperactivity Disorder Self-Report Scale Screener.

The aim of this study was to compare the performance of the 18-item Korean version of the World Health Organization adult attention-deficit/hyperactivity disorder self-report scale (ASRS) with the six...

Medical and Biotech [MESH] Definitions

A behavior disorder originating in childhood in which the essential features are signs of developmentally inappropriate inattention, impulsivity, and hyperactivity. Although most individuals have symptoms of both inattention and hyperactivity-impulsivity, one or the other pattern may be predominant. The disorder is more frequent in males than females. Onset is in childhood. Symptoms often attenuate during late adolescence although a minority experience the full complement of symptoms into mid-adulthood. (From DSM-IV)

A propylamine derivative and selective ADRENERGIC UPTAKE INHIBITOR that is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.

A methylphenidate derivative, DOPAMINE UPTAKE INHIBITOR and CENTRAL NERVOUS SYSTEM STIMULANT that is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.

A dextroamphetamine drug precursor that also functions as a CENTRAL NERVOUS SYSTEM STIMULANT and DOPAMINE UPTAKE INHIBITOR and is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.

The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.

More From BioPortfolio on "Phase I/II Single Center, Single-Treatment, Open-Label, Adaptive Clinical Trial Design Examining Pk of 2 MR Formulations of MPH in Adolescent/Pediatric With ADHD"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial